Level Chart

Basic Info

Vertex Pharmaceuticals Inc (VRTX) - Trikafta / Kaftrio Revenue is at a current level of 2.274B, up from 2.240B last quarter and up from 2.010B one year ago. This is a change of 1.51% from last quarter and 13.12% from one year ago.

Region United States
Source FinChat.io

Data provided via FinChat.io

Stats

Last Value 2.274B
Latest Period Sep 2023
Last Updated Jan 12 2024, 16:56 EST
Next Release Apr 30 2024, 08:30 EDT (E)
Average Growth Rate 56.42%
Value from Last Quarter 2.240B
Change from Last Quarter 1.51%
Value from 1 Year Ago 2.010B
Change from 1 Year Ago 13.12%
Frequency Quarterly
Unit USD
Adjustment N/A

Historical Data

View and export this data back to 2019. Upgrade now.
Date Value
September 30, 2023 2.274B
June 30, 2023 2.240B
March 31, 2023 2.097B
December 31, 2022 2.022B
September 30, 2022 2.010B
June 30, 2022 1.893B
March 31, 2022 1.762B
December 31, 2021 1.693B
Date Value
September 30, 2021 1.556B
June 30, 2021 1.256B
March 31, 2021 1.193B
December 31, 2020 1.091B
September 30, 2020 960.00M
June 30, 2020 918.00M
March 31, 2020 895.00M
December 31, 2019 420.00M

Basic Info

Vertex Pharmaceuticals Inc (VRTX) - Trikafta / Kaftrio Revenue is at a current level of 2.274B, up from 2.240B last quarter and up from 2.010B one year ago. This is a change of 1.51% from last quarter and 13.12% from one year ago.

Region United States
Source FinChat.io

Data provided via FinChat.io

Stats

Last Value 2.274B
Latest Period Sep 2023
Last Updated Jan 12 2024, 16:56 EST
Next Release Apr 30 2024, 08:30 EDT (E)
Average Growth Rate 56.42%
Value from Last Quarter 2.240B
Change from Last Quarter 1.51%
Value from 1 Year Ago 2.010B
Change from 1 Year Ago 13.12%
Frequency Quarterly
Unit USD
Adjustment N/A

Related Securities

Symbol Name Change %
VRTX Vertex Pharmaceuticals Inc -0.06%